Preventing Pneumococcal Disease through Vaccination
November 17, 2019 @ 9:10 AM - 9:40 AM
Streptococcus pneumoniae, or the pneumococcus, colonizes the nasopharynx, commonly causes local upper and lower respiratory infections including community-acquired pneumonia, and somewhat less commonly leads to invasive disease. Pneumococcal vaccines available in the US include a 23-valent polysaccharide vaccine (PPSV23) and a 13-valent protein conjugate vaccine (PCV13) and in June 2019, ACIP voted to recommend PCV13 for immunocompetent adults ≥65 years of age based on shared clinical decision making. This presentation will describe the impact of pneumococcal conjugate vaccines on the incidence of disease in children and adults, as well as the role of community protection provided by pneumococcal conjugate vaccines.